127 related articles for article (PubMed ID: 18974610)
1. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Shibata Y; Takahashi H; Chiba M; Ishii Y
Drug Metab Pharmacokinet; 2008; 23(5):328-39. PubMed ID: 18974610
[TBL] [Abstract][Full Text] [Related]
2. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
3. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
4. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
5. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
[TBL] [Abstract][Full Text] [Related]
6. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
McGinnity DF; Waters NJ; Tucker J; Riley RJ
Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketoconazole and quinidine on pharmacokinetics of pactimibe and its plasma metabolite, R-125528, in humans.
Kotsuma M; Tokui T; Freudenthaler S; Nishimura K
Drug Metab Dispos; 2008 Aug; 36(8):1505-11. PubMed ID: 18448569
[TBL] [Abstract][Full Text] [Related]
8. Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes.
Iwasaki S; Hirabayashi H; Amano N
Xenobiotica; 2018 Aug; 48(8):770-780. PubMed ID: 28851254
[TBL] [Abstract][Full Text] [Related]
9. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Shader RI
J Clin Pharmacol; 1994 Dec; 34(12):1222-7. PubMed ID: 7738219
[TBL] [Abstract][Full Text] [Related]
10. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
11. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
Youdim KA; Zayed A; Dickins M; Phipps A; Griffiths M; Darekar A; Hyland R; Fahmi O; Hurst S; Plowchalk DR; Cook J; Guo F; Obach RS
Br J Clin Pharmacol; 2008 May; 65(5):680-92. PubMed ID: 18279465
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
13. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.
Shibata Y; Takahashi H; Chiba M; Ishii Y
Drug Metab Dispos; 2002 Aug; 30(8):892-6. PubMed ID: 12124306
[TBL] [Abstract][Full Text] [Related]
14. Indinavir Increases Midazolam
Tian DD; Leonowens C; Cox EJ; González-Pérez V; Frederick KS; Scarlett YV; Fisher MB; Paine MF
Drug Metab Dispos; 2019 Jul; 47(7):724-731. PubMed ID: 31028057
[TBL] [Abstract][Full Text] [Related]
15. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.
Yamazaki S; Toth LN; Black ML; Duncan JN
Drug Metab Dispos; 2004 Apr; 32(4):398-404. PubMed ID: 15039292
[TBL] [Abstract][Full Text] [Related]
17. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes.
Lin C; Shi J; Moore A; Khetani SR
Drug Metab Dispos; 2016 Jan; 44(1):127-36. PubMed ID: 26452722
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.
Damle BD; Mummaneni V; Kaul S; Knupp C
Antimicrob Agents Chemother; 2002 Feb; 46(2):385-91. PubMed ID: 11796346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
